Open access · CC-BY
via OpenAlex
Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease
Yaping Chu, Warren D. Hirst, Howard J. Federoff, Ashley S. Harms, A. Jon Stoessl, Jeffrey H. Kordower
Brain · 2023 · ▲ 144 citations
Abstract
While Parkinson's disease remains clinically defined by cardinal motor symptoms resulting from nigrostriatal degeneration, it is now appreciated that the disease commonly consists of multiple pathologies, but it is unclear where these co-pathologies occur early in disease and whether they are responsible for the nigrostriatal degeneration. For the past number of years, we have been studying a well-characterized cohort of subjects with motor impairment that we have termed mild motor deficits. Motor deficits were determined on a modified and validated Unified Parkinson's Disease Rating Scale III but were insufficient in degree to diagnose Parkinson's disease. However, in our past studies, cases in this cohort had a selection bias, as both a clinical syndrome in between no motor deficits and Parkinson's disease, plus nigral Lewy pathology as defined post-mortem, were required for inclusion. Therefore, in the current study, we only based inclusion on the presence of a clinical phenotype with mild motor impairment insufficient to diagnose Parkinson's disease. Then, we divided this group further based upon whether or not subjects had a synucleinopathy in the nigrostriatal system. Here we demonstrate that loss of nigral dopaminergic neurons, loss of putamenal dopaminergic innervation and loss of the tyrosine hydroxylase-phenotype in the substantia nigra and putamen occur equally in mild motor deficit groups with and without nigral alpha-synuclein aggregates. Indeed, the common feature of these two groups is that both have similar degrees of AT8 positive phosphorylated tau, a pathology not seen in the nigrostriatal system of age-matched controls. These findings were confirmed with early (tau Ser208 phosphorylation) and late (tau Ser396/Ser404 phosphorylation) tau markers. This suggests that the initiation of nigrostriatal dopaminergic neurodegeneration occurs independently of alpha-synuclein aggregation and can be tau mediated.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/brain/awad388
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Chu, Y., Hirst, W.D., Federoff, H.J., Harms, A.S., Stoessl, A.J., & Kordower, J.H. (2023). Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease. <em>Brain</em>. https://doi.org/10.1093/brain/awad388
Vancouver
Chu Y, Hirst WD, Federoff HJ, Harms AS, Stoessl AJ, Kordower JH. Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease. Brain. 2023. doi:10.1093/brain/awad388.
BibTeX
@article{yaping2023Nigros,
title = {Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease},
author = {Yaping Chu and Warren D. Hirst and Howard J. Federoff and Ashley S. Harms and A. Jon Stoessl and Jeffrey H. Kordower},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awad388},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Trends in Biochemical Sciences 2015
Preprint · CC-BY
Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease
Behavioral Neuroscience 2014
Preprint · OA
Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson’s disease.
Cell Death and Disease 2012
Open access · CC-BY
Alpha-synuclein: from secretion to dysfunction and death
Neural Regeneration Research 2025
Open access · CC-BY
Imaging alpha-synuclein pathology in Parkinson’s disease
Aging Cell 2018
Open access · CC-BY
Tau protein aggregation is associated with cellular senescence in the brain
Scientific Reports 2019
Open access · CC-BY